|
|
StreetInsider.com
Apr 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Curis%2C+Inc.+%28CRIS%29+Misses+Q1+EPS+by+3c/8288699.html for the full story.
Mining Weekly
Apr 19
Comment
Toronto-listed Curis Resources on Friday said the Maricopa County Superior Court, in Arizona, has dismissed a lawsuit brought against Curis and the Arizona Department of Environmental Quality (ADEQ), challenging the validity of regulations...
Mining Weekly
Apr 2
Comment
The town council of Florence, Arizona, has rescinded an ordinance enacted in August 2012 that had effectively banned the use of large quantities of sulphuric acid by miners and other businesses, which now paved the way for mineral-development firm...
StreetInsider.com
Feb 20
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Curis%2C+Inc.+%28CRIS%29+Posts+Q4+Loss+of+15cShare/8114231.html for the full story.
Benzinga
Feb 19
Comment
Curis (NASDAQ: CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced the appointment of Ali Fattaey, Ph.D., as President and Chief Operating Officer. Dr. Fattaey will...
Mining Weekly
Feb 13
Comment
Canadian copper junior Curis Resources on Wednesday said it had completed a “positive” prefeasibility study (PFS) on its central Arizona property, which placed a pretax net present value (NPV) of $748-million on the project, at a 7.5% discount...
Benzinga
Dec 6
Comment
Curis (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Patent and Trademark Office has issued a patent covering a genus of...
FierceBiotech
Nov 28
Comment
Close to a year after Roche and its biotech partner Curis ($CRIS) gained FDA approval for the skin cancer drug Erivedge (vismodegib), the Lexington, MA-based company has pledged a portion of its revenue stream from that drug in exchange for a $30...
Benzinga
Nov 28
Comment
Curis (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has licensed from Genentech, a member of the Roche Group, (OTC: RHHBY),...
Benzinga
Nov 14
Comment
Stifel Nicolaus initiated coverage on Curis (NASDAQ: CRIS) with a Hold rating.
Stifel Nicolaus commented, "We forecast a steady, but somewhat lackluster launch trajectory for Erivedge, given the underwhelming adoption so far; CRIS' low royalty...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
